Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
26.4.2022 15:45:00 EEST | Business Wire | Press release
Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion’s personalized cancer immunotherapy EVX-01. The study will combine EVX-01, a neoepitope-targeting immunotherapy based on Evaxion’s proprietary PIONEER® AI technology, with KEYTRUDA® (pembrolizumab) for the treatment of patients with metastatic melanoma.
“We believe we have found the key to efficiently activating the immune system to combat cancer. With our core AI tool called PIONEER, we accurately predict the patient’s most potent neoepitopes, which are the significant mutations of cancer. Then we train the immune system to target those exact mutations, not everything else. That means a higher precision in the therapy than the standard of care treatments out there,” said Lars Wegner, CEO of Evaxion. “We are happy to work with Personalis on this crucial next step when we embark on the Phase 2b study, potentially bringing us closer to fulfilling our aspiration of saving the lives of patients with our AI-powered immunotherapy.”
“Over the past decade, a number of drugs have emerged based on the discovery that the immune system plays a key role in fighting cancer. However, the development of new therapies has been challenged by difficulties in understanding the precise interaction between cancer and the immune system,” said John West, CEO and co-founder of Personalis. “ImmunoID NeXT provides a broad set of insights on tumor and immune biology. Our collaboration with Evaxion may contribute to a better understanding of how combination therapeutics can improve patient outcomes and offer the path to companion diagnostics when relevant biomarkers are identified.”
ImmunoID NeXT® provides a comprehensive, multidimensional view of both a tumor and its immune microenvironment from a single sample. The platform consolidates multiple biomarker assays into one, including advanced analysis of mechanisms of tumor escape, human leukocyte antigen typing and loss of heterozygosity, microsatellite instability, gene expression signatures, T-cell and B-cell receptor repertoires, and immunocellular quantification. ImmunoID NeXT offers a seamless platform for discovery, from translational testing to companion diagnostics.
About Evaxion
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases and viral infections. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates, which currently includes three patient-specific cancer immunotherapies.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and follow Personalis on LinkedIn and Twitter.
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, expected benefits of Personalis’ collaboration with Evaxion, Personalis’ business opportunities, leadership, plans or expectations, or other future events. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, the company’s registration statement on Form S-3 filed on December 30, 2020, and the company’s prospectus supplement filed on January 3, 2022, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005194/en/
Contact information
Media Contact for Evaxion:
Katrine Hertz Mortensen
khm@evaxion-biotech.com
www.evaxion-biotech.com
+45 3010 0203
Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678
Media Contact for Personalis:
Jennifer Temple
pr@personalis.com
www.personalis.com
650-752-1300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Qorium Becomes Reyva as Cultivated Leather Company Moves Towards Commercial Scale2.11.2026 12:00:00 EET | Press release
Qorium, the company that develops cultivated real leather, today announces that it is becoming Reyva. The new name and identity mark its next stage: moving from a pioneering technology business towards a global material brand built for the exacting standards of the luxury leather sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102661351/en/ Reyva creates beautiful, high-performing real leather. By cultivating leather in uniform sheets, we can move beyond the natural limits of traditional hides, with greater control over its shape, size, thickness and structure. Reyva sample photography by Laurent Stevens Reyva grows collagen directly from animal cells and cultivates it through a proprietary process to create uniform sheets. The resulting material is then tanned to become real leather, made from the same natural material that gives conventional leather its strength, breathability and durability. It does so without t
Ant International Research Highlights How Readable AI Memories Can Unlock More Personalised, Privacy-conscious Consumer Experiences2.11.2026 10:52:00 EET | Press release
Human sales and customer representatives have institutional memories to serve clients: their preferences and choices. How can we build a memory mechanism for AI services to create similarly personalised experiences? Ant International’s research on this subject recently received the Senior Area Chair (SAC) Highlight Award from the Best Paper Committee at EMNLP 2026, a leading global AI conference. Why do we need “readable AI memory”? In this paper titled 'Text as a universal interface for transferable personalisation', we look into one fact: until now, AI memory of a user has usually been generated and stored as dense numerical code only the original system can interpret. Two long-standing problems with that: First, today's user profiles are "black boxes" — opaque code locked inside a single app, so activity in one service teaches nothing to another, and every product has to re-learn you from scratch. Second, profiles are welded to the model that created them, so they don't transfer whe
Car Connectivity Consortium Expands Focus on Digital Access for Two-Wheelers and Micromobility2.11.2026 10:00:00 EET | Press release
The Car Connectivity Consortium® (CCC), the global organization advancing interoperable connectivity between vehicles and devices, today highlighted its expanding work across the two-wheeler and micromobility markets ahead of EICMA 2026 in Milan, Italy. Through its Light Motor & Mobility Task Group (LMTG), CCC is bringing member companies together to address the distinct digital access needs of these markets and identify opportunities to advance standardization and interoperability. Key highlights of CCC's two-wheeler and micromobility work include: Addressing two-wheeler digital access needs: LMTG is examining requirements across motorcycles, scooters, e-bikes and other two- and three-wheeled vehicles. Exploring new applications for digital key technology: Member discussions include vehicle access and starting, access to vehicle components, and digital key sharing. Building broader industry participation: CCC will engage with manufacturers and technology companies at EICMA 2026 to dis
Liberis and Qred Complete Merger Following Regulatory Approval to Create Global SMB Financial Platform2.11.2026 10:00:00 EET | Press release
Liberis, a leading global embedded finance platform, and Qred, one of Europe’s foremost digital small business banks, today announced the completion of their merger, first announced in June 2026, following approval from the Swedish Financial Supervisory Authority (SFSA). The merger combines Qred’s regulated banking capability and direct relationships with small businesses with Liberis’s embedded finance technology and distribution through more than 30 partners, including Deliveroo, Vagaro and Nexi. The group serves more than 60,000 small businesses across 17 countries and has access to approximately 11.5 million addressable merchants. Qred’s deposit-funded banking model and direct customer relationships complement Liberis’s partner-led distribution. Together, the businesses bring two routes to small business finance: through a regulated bank and through platforms that businesses already use. The group’s ambition is to broaden the financial services available to small businesses and its
OpenGate Capital Completes the Acquisition of Maersk Training, the Global Safety Training and Gas Safety Services Business of Maersk2.11.2026 10:00:00 EET | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has completed the acquisition of Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Terms of the acquisition were not disclosed. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services and training. Through Maersk H2S Safety Services, the company provides specialized outsourced hydrogen sulphide and Health, Safety and Environment safety services for customers in high-risk operating environments. The H2S Safety Services team provides onsite supervision, monitoring and safety equipment maintenance where the safety of personnel and the protection of assets are critical. Through its training business, the company also delivers safety training, competency developmen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom